Targeting Lcn2 to Inhibit Myocardial Cell Ferroptosis is a Potential Therapy for Alleviating Septic Cardiomyopathy

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Cellular Pathology

Background:

• Septic cardiomyopathy (SCM) is a critical complication of sepsis, characterized by cardiac dysfunction.
• Ferroptosis, a regulated form of cell death, is increasingly recognized as a key contributor to SCM.
• Identifying molecular targets to mitigate ferroptosis is crucial for treating SCM.

Purpose of the Study:

• To investigate the role of ferroptosis in SCM pathogenesis.
• To identify novel therapeutic targets that can inhibit ferroptosis in cardiomyocytes during sepsis.
• To evaluate the potential of Lipocalin-2 (Lcn2) as a therapeutic target for SCM.

Main Methods:

• Integrated transcriptomic and proteomic analyses to identify key genes in SCM.
• Cecal ligation and perforation (CLP) model in mice to induce sepsis.
• Assessment of cardiac function, ferroptosis markers, inflammation, reactive oxygen species (ROS), and mitochondrial damage.

Main Results:

• Lipocalin-2 (Lcn2) was identified as a gene associated with SCM progression.
• Lcn2 knockout significantly suppressed cardiomyocyte ferroptosis in septic mice.
• Targeting Lcn2 led to reduced inflammation, lower ROS levels, alleviated mitochondrial damage, and restored cardiac function.

Conclusions:

• Lcn2 plays a significant role in promoting ferroptosis and cardiac dysfunction in SCM.
• Targeting Lcn2 emerges as a promising therapeutic strategy for SCM.
• Inhibition of Lcn2 can ameliorate cardiac injury by reducing ferroptosis, inflammation, and mitochondrial dysfunction.